Glycotope raises €55m for cancer drugs improved by human glycosylation
This article was originally published in Scrip
Executive Summary
German biotech firm Glycotope, which uses its GlycoExpress platform to improve drugs and drug candidates through "human" glycosylation, has raised €55m for the development of its two lead cancer drug candidates, PankoMab-GEX and CetuGEX. Both are in Phase IIb trials slated to complete by the end of 2016. The company's investors, which have now provided total financing in excess of €130m, are Munich-based Jossa Arznei (part of the Strüngmann group) and ELSA (Eckert Life Science Accelerator) in Berlin.